Who
Cynthia M. Patton
Director
Company insider
Files Form 4 as: Director, Organon & Co; SVP & Cco, Amgen.
In numbers
- Trades disclosed
- 96
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $5.0M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 26 Oct 2012
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K17,857.143 at $13.44 | filing |
| 12 Jun 2026filed 15 Jun 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K17,857.14 at $13.44 | filing |
| 13 Jun 2025filed 16 Jun 2025 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $240K23,904.38 at $10.04 | filing |
| 7 Jun 2024filed 11 Jun 2024 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K9,638.55 at $20.75 | filing |
| 9 Jun 2023filed 13 Jun 2023 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K10,086 at $19.83 | filing |
| 10 Jun 2022filed 14 Jun 2022 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $200K5,640 at $35.46 | filing |
| 4 Jun 2021filed 8 Jun 2021 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $316K8,772 at $36.05 | filing |
| 5 May 2020filed 7 May 2020 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —676 at $0.00 | filing |
| 5 May 2020filed 7 May 2020 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,668 at $0.00 | filing |
| 3 May 2020filed 5 May 2020 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $29K127 at $230.98 | filing |
| 1 May 2020filed 5 May 2020 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $28K115 at $239.22 | filing |
| 27 Apr 2020filed 29 Apr 2020 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $24K102 at $236.28 | filing |
| 20 Mar 2020filed 24 Mar 2020 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $294K1,481 at $198.76 | filing |
| 3 Mar 2020filed 5 Mar 2020 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —3,711 at $0.00 | filing |
| 30 Aug 2019filed 4 Sep 2019 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,749 at $0.00 | filing |
| 30 Aug 2019filed 4 Sep 2019 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,875 at $0.00 | filing |
| 30 Aug 2019filed 4 Sep 2019 | AMGN AmgenBiotechnology | SEC FORM 4 Code M | $899K5,749 at $156.35 | filing |
| 30 Aug 2019filed 4 Sep 2019 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $1.2M5,749 at $208.07 | filing |
| 30 Aug 2019filed 4 Sep 2019 | AMGN AmgenBiotechnology | SEC FORM 4 Code M | $467K2,875 at $162.60 | filing |
| 30 Aug 2019filed 4 Sep 2019 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $598K2,875 at $208.07 | filing |
News
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?AMGN · insidermonkey.com · 21 Oct 2026Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AMGN · fool.com · 20 Oct 2026AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026AMGN · prnewswire.com · 20 Oct 2026
0 headlines in the last 90 days name Cynthia M. Patton; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.